Supplement Dose Escalation Trials Help Foster Success – NCCAM’s Berman
This article was originally published in The Tan Sheet
Initial dose escalation trials will improve the success rate of dietary supplement clinical trials, according to director of NCCAM's Office of Clinical & Regulatory Affairs, Jonathan Berman, MD, PhD
You may also be interested in...
Preliminary data suggests the characterization of plants cited in adverse event reports published in medical literature is "woefully inadequate," according to Mary Hardy, MD, University of California - Los Angeles, Center for Dietary Research in Botanicals
A dose escalation study is a "very logical next step" for saw palmetto researchers to take, according to Heather Miller, PhD, of NCCAM's Division of Extramural Research & Training
The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association